Australian Prescriber An independent Review Logo

All Issues

Volume
 

IF YOU PRESCRIBE SUBSCRIBE

If you’re a health professional, subscribe to receive regular email updates from Australian Prescriber

Subscribe
  • empty

    Volume 45 Issue 2

    April 2022
  • April 2022

Oral antivirals for mild–moderate COVID‑19: a panacea or a logistical and clinical conundrum?

Covid-oral-antivirals-editorial-Getty Images-1357620708
Editorial Ian D Coombes, Amy Legg, Tina Patterson, Tanya Kelly, Andrew Henderson, Jason A Roberts
  • 1 April 2022
  • Podcast

The new oral antiviral drugs for COVID-19 were mainly studied in unvaccinated patients, before the emergence of the Omicron variant. Will they still be of benefit in 2022?
Article

Medicines for long-term obesity management

Joseph Proietto
  • 1 April 2022
  • Podcast
Article

The assessment of severe cutaneous adverse drug reactions

Ana M Copaescu, Jason A Trubiano
  • 1 April 2022
  • Podcast
Article

Antidepressants in adolescence

Philip Hazell
  • 1 April 2022
Abnormal laboratory results

Troponins in myocardial infarction and injury

Julia M Potter, Peter E Hickman, Louise Cullen
  • 1 April 2022
Letters to the Editor

Drugs for pain management in frail older people

Peter Maguire
  • 1 April 2022
Letters to the Editor

Statin doses after acute coronary syndrome

Simon B Dimmitt, Jennifer H Martin, Joanne Eng-Frost, Derek Chew
  • 1 April 2022
NEW DRUGS
Casirivimab and imdevimab for COVID-19
  • 1 April 2022
Molnupiravir for COVID-19
  • 1 April 2022
Nirmatrelvir and ritonavir for COVID-19
  • 1 April 2022
SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
  • 1 April 2022
Fostemsavir for HIV-1 infection
  • 1 April 2022
Lanadelumab for hereditary angioedema
  • 1 April 2022
Ravulizumab for paroxysmal nocturnal haemoglobinuria
  • 1 April 2022

IF YOU PRESCRIBE SUBSCRIBE

If you’re a health professional, subscribe to receive regular email updates from Australian Prescriber

Subscribe
Online tool
94709A0Fe3Ce0D7F C3839A5F91F1 Doctors Bag Hero